CAR-T and Cell Therapy Patent Landscape in 2026
Writen By:
Cypris Research Team
CAR-T cell therapy has one of the most academically rooted and legally tested patent landscapes in biotechnology. A chimeric antigen receptor T-cell is engineered by giving a patient's T-cells a synthetic receptor that directs them against a cancer target, and the intellectual property spans several distinct layers: the CAR construct itself, with its antigen-binding domain, hinge, transmembrane region, costimulatory domain, and signaling domain; the viral vectors used to introduce it; the manufacturing and cell-processing methods; and the methods of use for specific indications. Because these layers are patented separately and often by different owners, freedom-to-operate for a CAR-T product is a multi-layer, multi-owner analysis rather than a single clearance.
The foundational patents emerged from academic laboratories and were then in-licensed or acquired by commercial developers, which shaped the ownership structure. Peer-reviewed analyses of CAR-T patenting activity trace the field's key early filings to academic groups, with foundational work associated with Carl June at the University of Pennsylvania and Michel Sadelain at Memorial Sloan Kettering Cancer Center, before commercialization by large pharmaceutical companies.¹,² This academic origin is visible in the ownership record: across the Cypris corpus of more than 500 million patents and scientific papers, the most active assignees in the CAR-T set are led by the University of Pennsylvania, followed by the US Department of Health and Human Services and the National Institutes of Health, the University of California San Diego, the University of Texas System, and Memorial Sloan Kettering, interleaved with commercial developers such as Novartis, Juno Therapeutics, and Kite Pharma. Peer-reviewed patent-landscape analyses describe a field of fierce competition and intensive academic-industry collaboration,¹ with one review mapping more than 1,600 patent families across the field's technological routes,³ and product-patent-linkage studies have detailed how the portfolios behind approved CAR-T products are assembled from the construct, vector, manufacturing, and method-of-use layers.⁴ Analyses of academic CAR-T patenting also document the pitfalls that arise when university filings are drafted for disclosure rather than durable claim scope.⁵ A recurring finding is that many foundational filings date to the late 1990s and early 2000s, so their earliest members are now reaching the end of their patent terms, which shifts value toward improvement patents on next-generation constructs, allogeneic and off-the-shelf approaches, and manufacturing.¹,³ Across the Cypris corpus, CAR-T patent families grew from about 2,882 in 2018 to about 9,118 in 2024, with 2025 counts partial because of the roughly eighteen-month publication lag.
Litigation defined the landscape's risk profile. In the dispute between Juno Therapeutics, which exclusively licensed a foundational receptor patent from Memorial Sloan Kettering, and Kite Pharma over its approved therapy, a jury initially found for Juno, but on August 26, 2021 the US Court of Appeals for the Federal Circuit reversed and held the foundational patent's asserted claims invalid for lack of adequate written description, reasoning that disclosing a small number of specific binding domains did not show possession of the far broader claimed genus.⁶ A peer-reviewed analysis in Biotechnology Law Report situated the decision as a strike against broadly drafted, pioneering biotechnology claims.⁷ The decision reshaped the field, because it raised questions about the validity of broadly drafted foundational biotech patents generally, and it signaled that in cell therapy the durable value may lie in specific, well-supported improvement claims rather than pioneering-but-broad foundational ones. Because applications publish about eighteen months after filing, the most recent activity in next-generation and allogeneic approaches is under-represented, so the current frontier is more active than granted-patent counts suggest.
What creates FTO risk in CAR-T products
CAR construct claims. These cover the receptor's components, including antigen-binding domain, costimulatory domain, and signaling domain, the core of many disputes.
Viral vector claims. These cover the vectors used to introduce the receptor, a distinct and separately owned layer.
Manufacturing and cell-processing claims. These cover how the therapy is produced, which is increasingly where competitive differentiation and IP concentrate.
Method-of-use claims. These cover use for specific indications and patient populations, so a construct can be free for one use and blocked for another.
Next-generation and allogeneic claims. These cover off-the-shelf, gene-edited, and next-generation approaches, a fast-growing layer where new FTO risk and white space are emerging.
How AI-powered landscape and FTO analysis helps
A multi-layer, academically rooted, litigated landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant construct, vector, manufacturing, and use claims regardless of terminology, attribution that resolves academic and commercial owners to canonical entities and captures the license and acquisition chains, and continuous monitoring that tracks next-generation filings and litigation developments. Because cell-therapy advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning.
Where Cypris fits
Cypris runs patent landscape and freedom-to-operate analysis for multi-layer, academically rooted fields such as CAR-T across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, construct, vector, manufacturing, and use, and normalizes academic and commercial owners to canonical entities, so a team can trace how rights and licenses are distributed rather than read a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where next-generation and allogeneic approaches emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
Why is the CAR-T patent landscape distinctive? The CAR-T patent landscape is distinctive because it is deeply rooted in academic research and has been heavily litigated. Foundational patents came from university labs and were licensed or acquired by commercial developers, and the IP spans the receptor construct, viral vectors, manufacturing, and methods of use. Freedom-to-operate is therefore a multi-layer, multi-owner analysis.
What claim types create FTO risk in CAR-T? Five claim types create FTO risk in CAR-T: CAR construct claims, viral vector claims, manufacturing and cell-processing claims, method-of-use claims, and next-generation or allogeneic claims. Each is independently patentable and can be held by a different owner. Construct and manufacturing layers are especially contested.
What was the Juno v. Kite decision? In Juno v. Kite, Juno Therapeutics asserted a foundational CAR receptor patent it had licensed from Memorial Sloan Kettering against Kite Pharma's approved therapy. A jury initially found for Juno, but the US Court of Appeals for the Federal Circuit in 2021 reversed and struck down the foundational patent for lack of adequate written description. The decision reshaped the field and raised questions about broadly drafted foundational biotech patents.
Why are CAR-T foundational patents reaching the end of their terms important? Many CAR-T foundational filings date to the late 1990s and early 2000s, so their earliest members are now reaching the end of their patent terms, which shifts value away from the original broad claims toward improvement patents. These cover next-generation constructs, allogeneic and off-the-shelf approaches, and manufacturing. FTO analysis must therefore focus increasingly on the improvement layer.
Where did CAR-T foundational patents come from? CAR-T foundational patents came largely from academic laboratories, with key work associated with Carl June at the University of Pennsylvania and Michel Sadelain at Memorial Sloan Kettering Cancer Center. These filings were in-licensed or acquired by commercial developers who brought products to market. This academic origin shaped the landscape's ownership and licensing structure, which is visible in the assignee record.
Why does CAR-T analysis need scientific literature? CAR-T analysis needs scientific literature because construct, manufacturing, and next-generation advances appear in research before they are patented, so the literature gives the earliest signal of where the field is heading. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.
Which teams need CAR-T patent landscape and FTO analysis? CAR-T patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at cell-therapy and pharmaceutical companies, academic technology-transfer offices, and investors assessing cell-therapy assets. The multi-layer, litigated landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.
How current does a CAR-T landscape need to be? A CAR-T landscape needs to be continuously current, because foundational patents are reaching the end of their terms, next-generation and allogeneic filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track the landscape and flag new filings and developments as they publish.
Endnotes
- Lyu, L., Chen, X., Hu, Y., & Feng, Y. (2020). The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape. Nature Biotechnology, 38(12). https://doi.org/10.1038/s41587-020-00749-8
- Clarke, N. S., & Jürgens, B. (2019). Evolution of CAR T-cell immunotherapy in terms of patenting activity. Nature Biotechnology, 37(4). https://doi.org/10.1038/s41587-019-0083-5
- Malmegrim, K. C. R., Picanço-Castro, V., Pereira, C. G., Covas, D. T., Porto, G. S., & Swiech, K. (2019). Emerging CAR T cell therapies: clinical landscape and patent technological routes. Human Vaccines & Immunotherapeutics, 16(6). https://doi.org/10.1080/21645515.2019.1689744
- Kano, S., & Kawai, Y. (2025). Expanding the concept of drug lifecycle management to chimeric antigen receptor T-cell products through product-patent linkage analysis. World Patent Information, 81. https://doi.org/10.1016/j.wpi.2025.102357
- Constantinescu, C., Gulei, D., Bergþorsson, J. Þ., Coliţă, A., Tănase, A., Tomuleasa, C., Greiff, V., & Constantinescu, R. (2023). Pitfalls in patenting academic CAR-T cells therapy. Expert Opinion on Therapeutic Patents, 33(6). https://doi.org/10.1080/13543776.2023.2220883
- U.S. Court of Appeals for the Federal Circuit (Aug. 26, 2021). Juno Therapeutics, Inc. v. Kite Pharma, Inc., 10 F.4th 1330. https://www.cafc.uscourts.gov/opinions-orders/20-1758.opinion.8-26-2021_1825257.pdf
- Holman, C. M. (2021). In Juno v. Kite the Federal Circuit strikes down patent directed towards pioneering innovation in CAR T-cell therapy. Biotechnology Law Report, 40(6). https://doi.org/10.1089/blr.2021.29252.cmh
.jpg)